HK1244667A1 - 预防二次感染的方法 - Google Patents

预防二次感染的方法 Download PDF

Info

Publication number
HK1244667A1
HK1244667A1 HK18103208.2A HK18103208A HK1244667A1 HK 1244667 A1 HK1244667 A1 HK 1244667A1 HK 18103208 A HK18103208 A HK 18103208A HK 1244667 A1 HK1244667 A1 HK 1244667A1
Authority
HK
Hong Kong
Prior art keywords
methods
secondary infections
preventing secondary
pathogen
effective amount
Prior art date
Application number
HK18103208.2A
Other languages
English (en)
Chinese (zh)
Inventor
Irit Sagi
Dalit TALMI-FRANK
Inna SOLOMONOV
Ido Amit
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of HK1244667A1 publication Critical patent/HK1244667A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK18103208.2A 2015-02-09 2016-02-09 预防二次感染的方法 HK1244667A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113551P 2015-02-09 2015-02-09
US62/113,551 2015-02-09
PCT/IL2016/050156 WO2016128975A1 (en) 2015-02-09 2016-02-09 Methods of preventing secondary infections

Publications (1)

Publication Number Publication Date
HK1244667A1 true HK1244667A1 (zh) 2018-08-17

Family

ID=56615084

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103208.2A HK1244667A1 (zh) 2015-02-09 2016-02-09 预防二次感染的方法

Country Status (7)

Country Link
US (2) US10610588B2 (enExample)
EP (1) EP3256135A4 (enExample)
JP (2) JP6783777B2 (enExample)
BR (1) BR112017017115A2 (enExample)
CA (1) CA2974925C (enExample)
HK (1) HK1244667A1 (enExample)
WO (1) WO2016128975A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974925C (en) 2015-02-09 2022-03-22 Yeda Research And Development Co. Ltd. Methods of preventing secondary infections
USD841023S1 (en) * 2017-08-24 2019-02-19 Domo, Inc. Display screen or portion thereof with a graphical user interface
JP2023530997A (ja) * 2020-06-19 2023-07-20 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
WO2004064728A2 (en) 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
EP1624866A2 (en) 2003-05-16 2006-02-15 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
US7910620B2 (en) * 2005-04-22 2011-03-22 Broadhurst Iii Jack J Uses of neuraminidase inhibitors in infectious diseases
WO2015031654A2 (en) * 2013-08-28 2015-03-05 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
CA2974925C (en) 2015-02-09 2022-03-22 Yeda Research And Development Co. Ltd. Methods of preventing secondary infections

Also Published As

Publication number Publication date
US20180028650A1 (en) 2018-02-01
EP3256135A4 (en) 2018-06-27
JP2018507847A (ja) 2018-03-22
WO2016128975A1 (en) 2016-08-18
JP7109515B2 (ja) 2022-07-29
BR112017017115A2 (pt) 2018-04-03
JP2021020936A (ja) 2021-02-18
CA2974925C (en) 2022-03-22
US20200261577A1 (en) 2020-08-20
US11400156B2 (en) 2022-08-02
JP6783777B2 (ja) 2020-11-11
EP3256135A1 (en) 2017-12-20
CA2974925A1 (en) 2016-08-18
US10610588B2 (en) 2020-04-07

Similar Documents

Publication Publication Date Title
MX2017009716A (es) Anticuerpos humanos contra glicoproteina del virus ebola.
PH12018502673A1 (en) Anti-zika virus antibodies and methods of use
PH12017500949A1 (en) Human antibodies to influenza hemagglutinin
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112017011900A2 (pt) tratamento de ataques com fosfatase alcalina recombinante
MX376691B (es) Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
WO2014134583A3 (en) Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
TW201613575A (en) Treatment of polybacterial infections
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
MX369474B (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
IN2013MU01696A (enExample)
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
PH12017501806A1 (en) Anthelmintic combinations and methods of use thereof
EA201791051A1 (ru) Способ лечения, профилактики или снижения риска возникновения кожной инфекции
WO2014152437A3 (en) Methods of use for an antimicrobial peptide
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
WO2014107685A3 (en) Compositions and methods for using huperzine and analogs thereof
EA201170970A1 (ru) Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом
WO2014160088A3 (en) Treating hepatitis b virus infections
MX388699B (es) Formas cristalinas de cabotegravir de sodio
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
MY192972A (en) A specific trifluoroethyl quinoline analogue for use in the treatment of sjogren's syndrome